Findings from a biomarker analysis of the phase 3 AtTEnd trial (NCT03603184) indicate that high whole-exome sequencing (WES)–aneuploidy scores (W-AS) may serve as a...
The treatment landscape for hepatocellular carcinoma (HCC) is evolving, particularly with the refinement of first-line immunotherapy strategies. In a recent discussion on the podcast...